Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
44.20
-0.60 (-1.33%)
Jan 31, 2025, 10:49 AM EST - Market open
Janux Therapeutics Employees
Janux Therapeutics had 64 employees as of December 31, 2023. The number of employees increased by 4 or 6.67% compared to the previous year.
Employees
64
Change (1Y)
4
Growth (1Y)
6.67%
Revenue / Employee
$203,891
Profits / Employee
-$945,875
Market Cap
2.55B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 64 | 4 | 6.67% |
| Dec 31, 2022 | 60 | 27 | 81.82% |
| Dec 31, 2021 | 33 | 21 | 175.00% |
| Dec 31, 2020 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
JANX News
- 6 days ago - Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer - Business Wire
- 23 days ago - Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data - Seeking Alpha
- 4 weeks ago - Best-Performing Stocks Of 2024 - Seeking Alpha
- 7 weeks ago - Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire
- 2 months ago - Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
- 2 months ago - Janux Therapeutics Announces Proposed Public Offering - Business Wire
- 2 months ago - Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst - Benzinga
- 2 months ago - Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results - Barrons